Global Stem Cells Group Partners with StemBio to Advance Regenerative Medicine Research and Development
Miami, Florida— Global Stem Cells Group, a leader in regenerative medicine, is thrilled to announce a strategic partnership with StemBio, a renowned leader in the regenerative medicine landscape in Turkey. This partnership aims to propel research and development, conduct clinical trials, and create new products and protocols for the advancement of regenerative medicine.
StemBio, a trailblazer in Turkey, possesses all the necessary licenses and state-of-the-art infrastructure for regenerative medicine, including Bone Marrow Derived MSC, Adipose Derived MSC, Umbilical cord, placenta, Wharton jelly Derived MSC, Synovial Derived MSC, and more. We believe this diverse range of resources demonstrates StemBio’s commitment to excellence, making them one of the foremost facilities for regenerative medicine in Turkey.
This collaboration brings together two powerhouses in the regenerative medicine arena, aiming to break new ground in the research, development, and application of regenerative therapies. We believe the collective expertise and resources of StemBio and Global Stem Cells Group are set to drive innovation and advancements in regenerative care, benefiting patients worldwide.
“We are excited to partner with StemBio and leverage their expertise in regenerative medicine. This partnership should accelerate our mission to provide cutting-edge regenerative solutions to a global audience,” said Benito Novas, head of relationships at Global Stem Cells Group.
We believe the partnership between StemBio and Global Stem Cells Group signifies a significant milestone in the regenerative medicine field. As they combine their strengths and knowledge, they are committed to pushing the boundaries of what is possible in regenerative care and making a lasting impact on patients’ lives.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
About StemBio:
StemBio is a renowned regenerative medicine facility in Turkey, equipped with cutting-edge infrastructure and a commitment to excellence. Holding the necessary licenses for cord blood and tissue banking, as well as advanced engineering solutions, StemBio is a leader in the regenerative medicine landscape.
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in News
Advancements in Hair Transplantation: A Paradigm Shift in Regenerative Medicine
In the realm of regenerative medicine, hair transplantation has experienced remarkable progress in recent years. As part of a multidisciplinary community of physicians and scientists dedicated to advancing the field, it is essential to stay informed about the latest developments in this area. This blog post aims to provide a comprehensive overview of the cutting-edge advancements in hair transplantation, highlighting the convergence of science, technology, and practice.
Tissue Engineering in Hair Transplantation:
The integration of tissue engineering principles into hair transplantation has opened new avenues for regenerative medicine. Scientists are actively exploring the use of biomaterials, growth factors, and scaffolds to create an optimal environment for transplanted hair follicles. By nurturing follicular cells, tissue engineering techniques hold immense potential in enhancing transplantation outcomes and promoting tissue regeneration.
Stem Cell-Based Approaches:
Stem cell therapy has emerged as a promising strategy within the realm of hair transplantation. Researchers are investigating the utilization of mesenchymal stem cells (MSCs) and adipose-derived stem cells (ADSCs) to stimulate hair follicle regeneration. These unique regenerative cells promote hair growth and significantly enhance the success rate of transplantation procedures. Ongoing research in stem cell-based therapies continues to unveil their potential to revolutionize hair restoration techniques.
Gene Therapy for Hair Loss:
Gene therapy is gaining traction as a cutting-edge approach to addressing hair loss at its core. Scientists aim to develop innovative treatments for both genetic and acquired forms of hair loss by manipulating genes involved in hair growth and regulation. Techniques such as CRISPR-Cas9 gene editing hold immense potential for altering gene expression associated with hair follicle development, offering personalized regenerative therapies.
Nanotechnology in Hair Transplantation:
Nanotechnology has paved the way for groundbreaking advancements in hair transplantation. Researchers are exploring the application of nanomaterials and nanoparticles to enhance the targeted delivery of growth factors, drugs, and stem cells directly to the hair follicles. This precise and controlled release optimizes the regenerative potential of transplanted hair follicles, leading to improved treatment outcomes and faster healing.
Artificial Intelligence (AI) and Machine Learning:
The integration of AI and machine learning algorithms has transformed various medical fields, including hair transplantation. AI-powered technologies assist in precise hair follicle extraction, optimizing graft placement, and predicting post-transplant outcomes. By analyzing vast datasets and patterns, AI algorithms enhance decision-making, improve surgical techniques, and contribute to personalized treatment plans in hair transplantation.
As active contributors to the advancement of regenerative medicine, staying informed about the latest developments in hair transplantation is crucial. Tissue engineering, stem cell-based approaches, gene therapy, nanotechnology, and the integration of AI and machine learning are reshaping the landscape of hair restoration. By remaining at the forefront of these advancements, physicians and scientists can harness the power of regenerative medicine to effectively treat hair loss and alleviate human suffering.
Join us at Issca.com and let us continue to collaborate, innovate, and explore the limitless potential of regenerative therapies.
- Published in Blog
International Society for Stem Cell Applications Launches Advanced Turkish Hair Transplant Certification Program in Cancun
Miami, Florida – The International Society for Stem Cell Applications (ISSCA) is thrilled to announce the launch of its newest program, the Advanced Turkish Hair Transplant Certification. This pioneering training and certification initiative will take place from December 8th to 10th at the prestigious Cellular Hope Institute Facility in Cancun, Mexico. Physicians are encouraged to register promptly as the program is expected to fill up quickly.
Turkey has earned a global reputation for providing the finest hair transplants worldwide. Some of the hair transplant experts from Turkey who have developed and perfected this procedure are now willing to share their secrets with any physician who seeks to excel in hair restoration procedures in their home country. The demand for hair regrowth, hair restoration, and hair transplant procedures is growing by the day as men and women realize they do not have to suffer from the embarrassment of thinning hair and bare scalps anymore.
The Advanced Turkish Hair Transplant Certification program offers a comprehensive curriculum encompassing cutting-edge hair transplant procedures. Participants will engage in both theoretical and practical training sessions, helping to assist their mastery of this rapidly expanding field. They will have the extraordinary opportunity to practice hair transplant surgeries under the supervision and guidance of world-renowned experts in the field, including Veysel Cabalar, Asli Uslu, and Emere Tuncinar, who bring their wealth of experience and knowledge to the program.
In addition to hair transplant surgery, the program’s curriculum will cover workshops on advanced hair restoration techniques such as exomes, stem cells, and platelet-rich plasma treatments. Participants will learn how to select suitable patients for these different hair restoration methods and gain hands-on experience in preparing, storing, and administering exosomes, stem cells, and platelet-rich plasma to promote hair regrowth. Armed with this expertise, we believe participants will return to their own clinics with confidence, ready to deliver these transformative procedures for the benefit of their patients.
Dr. Salih Yildirim, ISSCA President, expressed his delight in fulfilling the organization’s mission of expanding the reach of new regenerative medicine technologies to doctors and patients worldwide: “The Advanced Turkish Hair Transplant Certification program exemplifies our commitment to advancing the field of regenerative medicine. We are proud to provide doctors with the tools and knowledge to bring the latest hair restoration techniques to their patients.”
Benito Novas, ISSCA Vicepresident , added, “We are excited to bring this groundbreaking Turkish training to Cancun, offering local doctors and physicians across Latin America the opportunity to learn from the best. Our collaboration with the Cellular Hope Institute Facility underscores our dedication to providing exceptional educational experiences that benefit medical professionals and patients alike.”
The program will include theoretical sessions on scalp and hair follicle anatomy, patient evaluation, and surgical preparation for hair transplant procedures. Detailed workshops on graft extraction and implantation techniques will also be conducted, enabling participants to refine their skills and achieve realistic, outstanding results. From patient evaluations to postoperative care protocols, the hands-on surgical sessions will encompass every aspect of the hair transplant process.
The Advanced Turkish Hair Transplant Certification program by ISSCA offers an invaluable opportunity for doctors seeking to excel in the field of hair transplantation. Participants will gain comprehensive knowledge, refine their surgical techniques, and stay abreast of the latest advancements in hair regrowth, hair restoration, and hair transplants.
To learn more about the Advanced Turkish Hair Transplant Certification program and register for this transformative educational experience, please visit the official ISSCA website at www.issca.com.
About ISSCA
The International Society for Stem Cell Applications (ISSCA) is a multidisciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through advances in regenerative medicine. By bringing together worldwide researchers and healthcare practitioners, ISSCA aims to bridge the gap between cutting-edge scientific research and compassionate, effective patient care.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a world-renowned leader in regenerative medicine, specializing in innovative solutions that harness the power of stem cells for therapeutic applications. With a global network of offices and an unwavering commitment to excellence, GSCG continues to shape the future of regenerative and restorative medicine through groundbreaking products and advanced treatment protocols.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in News
Ozone Therapy: A Promising Alternative Treatment with Potential Benefits
Ozone therapy is a promising alternative medical treatment that has gained popularity in recent years. It involves the administration of ozone, a form of oxygen, to treat various medical conditions, ranging from chronic pain to infections. Although the scientific evidence on the effectiveness of ozone therapy remains limited, many people claim to have experienced significant health benefits from this alternative treat
ment. In this article, we’ll explore the potential benefits and risks of ozone therapy, as well as the latest research on this alternative medical treatment.
What is ozone therapy?
Ozone therapy is a safe, non-invasive, and effective alternative medical treatment that has been used for over a century. It involves the administration of ozone, a gas made up of three oxygen atoms, to the body in various forms, such as injections, insufflations, or topical applications. Ozone is a powerful oxidant that can damage cells and tissues, which can have positive or negative effects, depending on the form and amount of ozone used.
One of the key benefits of ozone therapy is its ability to improve blood circulation and oxygen delivery to the tissues, which can help reduce inflammation, support wound healing, and boost immune function. Additionally, ozone therapy is believed to have antimicrobial and antiviral properties, which may help fight infections caused by bacteria, viruses, and fungi.
What are the potential benefits of ozone therapy?
Ozone therapy has been used to treat a wide range of medical conditions, including:
- Chronic pain: Ozone therapy may help reduce pain and inflammation in conditions such as osteoarthritis, herniated discs, and fibromyalgia.
- Infections: Ozone therapy may help fight infections caused by bacteria, viruses, and fungi, including Lyme disease, hepatitis, and HIV.
- Autoimmune diseases: Ozone therapy may help reduce inflammation and improve immune function in conditions such as multiple sclerosis, rheumatoid arthritis, and lupus.
- Skin conditions: Ozone therapy may help treat various skin conditions, including eczema, psoriasis, and acne, by improving blood circulation and oxygenation.
Moreover, ozone therapy is a safe and non-invasive treatment that doesn’t have the side effects commonly associated with traditional medical treatments. It’s also relatively inexpensive and can be administered in a variety of settings, including clinics, hospitals, and private practices.
What does the latest research say about ozone therapy?
Although the scientific evidence on the effectiveness and safety of ozone therapy remains limited, some recent studies have suggested that ozone therapy may have potential health benefits in certain conditions.
A study published in the Cuban journal of immunology describes the immunomodulatory properties of ozone therapy by characterizing the biological effects of ozone on immune system cells, soluble mediators and other cell types.
In another example, in a 2022 review on ozone therapy in pain medicine, authors agree on the high safety of pain treatments with ozone therapy, especially modern medical ozone generators with great precision. Similarly, a 2020 study on Systemic ozone therapy in insulin-dependent diabetic patients found that the analgesic and anti-inflammatory properties of ozone currently make it one of the most efficient therapeutic tools for the control of chronic pain in insulin-dependent diabetic patients.
Ultimately, ozone therapy is a promising alternative medical treatment that has been used to treat various medical conditions. Many people claim to have experienced significant health benefits from this alternative treatment. Furthermore, ozone therapy is a safe and non-invasive treatment that doesn’t have the side effects commonly associated with traditional medical treatments.
If you’re interested in ozone therapy, make sure to do your research, ask questions, and consider this alternative medical treatment as a potential option for your health concerns. It’s important to stay informed about the latest developments in stem cell therapy. You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us
- Published in Blog
Personalized Regenerative Medicine: The Future of Regenerative Medicine
Regenerative medicine is a rapidly growing field that focuses on repairing or replacing damaged or diseased tissues and organs using stem cells, growth factors, and other advanced therapies. The effectiveness of this approach has been demonstrated in treating a wide range of conditions, including heart disease, diabetes, joint pain, and neurological disorders. One of the major challenges of regenerative medicine, however, is that not every patient responds to the same treatment. This is where personalized regenerative medicine comes into play.
What is Personalized Regenerative Medicine?
Personalized regenerative medicine involves tailoring treatments to meet the unique needs of each patient based on their genetic profile, lifestyle, and medical history. This approach recognizes that no two patients are the same, and that a one-size-fits-all approach to regenerative medicine is not always effective.
As part of personalized regenerative medicine, advanced technologies such as genomics, proteomics, and metabolomics are used to analyze a patient’s unique biological profile. In order to provide customized and targeted treatment to patients, regenerative medicine centers utilize this information to develop personalized treatment plans tailored to their individual needs and conditions, ranging from stem cell therapy to gene therapy.
Why is Personalized Regenerative Medicine the Future of Regenerative Medicine?
There are several reasons why personalized regenerative medicine is the future of regenerative medicine:
- More effective treatments: By tailoring treatments to individual patients, personalized regenerative medicine has the potential to be much more effective than traditional one-size-fits-all approaches.
- Improved patient outcomes: Because personalized regenerative medicine takes into account the unique needs and conditions of each patient, it has the potential to improve patient outcomes and reduce the risk of complications.
- Lower healthcare costs: By providing more effective treatments and reducing the risk of complications, personalized regenerative medicine has the potential to lower healthcare costs in the long run.
- Better understanding of disease: Personalized regenerative medicine involves analyzing a patient’s unique biological profile, which can help researchers and healthcare providers better understand the underlying mechanisms of disease.
- Advancements in technology: As technology continues to advance, personalized regenerative medicine will become even more precise and effective, leading to even better patient outcomes.
The concept of personalized regenerative medicine is an exciting new approach to regenerative medicine that has the potential to revolutionize the healthcare industry. Individualized regenerative medicine has the potential to be more effective, improve patient outcomes, lower healthcare costs, and provide better understanding of disease by tailoring treatments to the individual patient. As technology continues to advance, we can expect to see even more exciting developments in this field in the years to come.
You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us
- Published in Blog
Revolutionizing Neurodegenerative Care: The Advancements in Stem Cell Therapy
Neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis, are a group of incurable neurological disorders, characterized by the chronic progressive loss of different neuronal subtypes. The conditions are debilitating and affect millions of people worldwide. Despite its increasing prevalence among the ever-increasing aging population, little progress has been made in the coincident immense efforts towards development of therapeutic agents. However, recent advancements in stem cell therapy including stem cells-derived exosomes, neurotrophic factors (NTFs), and their combination as potential therapeutic agents in neurodegenerative diseases.
In recent years, stem cells have emerged as one of the most active research therapeutic tools for many diseases. Stem cells are undifferentiated cells that have the ability to develop into pluripotent stem cells and adult stem cells. All stem cells have the potentiality of continuous self-renewal, high proliferation, and multidirectional differentiation into various cell types to replace degenerated or dead cells. In the context of neurodegenerative diseases, stem cells can be used to replace lost or damaged neurons, provide neuroprotection, and promote neural repair. These properties make stem cells an attractive option for treating neurodegenerative diseases, as they have the potential to slow or even reverse the progression of these conditions.
One of the key benefits of stem cell therapy for neurodegenerative diseases is that it offers a non-invasive, minimally-invasive, and non-toxic alternative to traditional treatments. Unlike drugs and surgery, stem cell therapy does not produce adverse side effects, and can be administered in a safe and controlled manner. In clinical trials, stem cell therapy has been shown to be effective in reducing symptoms and improving quality of life for patients with neurodegenerative diseases.
- Alzheimer’s disease (AD)
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the most common form of dementia, affecting approximately 55 million people worldwide. Cognitive impairment is a hallmark of AD. Currently, drug therapies can only delay symptoms, but not relieve disease pathology or progression. Researchers have demonstrated that neurons derived from stem cells can integrate with existing neural networks and repair damaged neurons within the host brain, improving learning and memory deficits, and NTFs can improve AD symptoms and provide neuroprotective effects.
- Parkinson’s disease (PD)
The second most common neurodegenerative disorder is Parkinson’s disease (PD). The motor symptoms of PD mainly include rest tremor, rigidity, bradykinesia and postural instability, while common nonmotor symptoms include neuropsychiatric and sleep disorders as well as sensory and autonomic dysfunction. At present, there is no cure for PD or disease-modifying therapy. It is common for symptom-relief medications to only provide partial relief and elicit side effects such as motor complications, gastrointestinal problems, and neurological issues. In spite of the fact that these treatments do not address the underlying pathology, alternative therapies, especially those based on stem cells and NTFs, are still being pursued intensively.
- Huntington’s disease (HD)
Huntington’s disease (HD) is characterized by motor, cognitive, and psychiatric dysfunctions. The study of multiple possible neurodegenerative mechanisms of HD is currently underway, and this knowledge is expected to contribute to the development of new HD treatments. The abilities of stem cells to rescue or replace the damaged and dying neurons, and to prevent further cell damage and death, make stem cell-based therapies promising for treatment of this neurode-generative disease.
- Amyotrophic lateral sclerosis (ALS)
As a neurodegenerative disorder, amyotrophic lateral sclerosis (ALS) involves progressive degeneration of both upper and lower motor neurons, resulting in palsy and death within 3-5 years of onset. Currently, only two disease-modifying medicines are available, each showing benefit to a limited number of patients. Stem cell-based therapy holds great promise for treating ALS by providing both cell replacement and NTF delivery to target the multiple pathologies. Stem cells available for ALS treatment include NSCs, MSCs, embryonic stem cells, induced pluripotent stem cells, and olfactory ensheathing stem cells.
While stem cell therapy is still in the early stages of development, it holds enormous promise as a future treatment for neurodegenerative diseases. A number of studies have demonstrated that stem cells and NTFs offer considerable therapeutic potential, especially when they are used together. In addition to replenishing target neurons, stem cells combined with NTFs can produce neurotrophins to improve the microenvironment that promotes nerve repair and regeneration. As research continues, we can expect to see even more exciting advancements in this field, bringing hope to those affected by these debilitating conditions.
It’s important to stay informed about the latest developments in stem cell therapy. You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us
- Published in Blog
ISSCA is Pleased to Announce the Launch of its Comprehensive Online Course in Regenerative and Functional Medicine for Obesity Management
The International Society for Stem Cell Application (ISSCA) is proud to announce the launch of its latest online course, “Curso en Medicina Funcional Regenerativa y Obesidad / Course in Functional Regenerative Medicine and Obesity.” This comprehensive course is designed to provide students with a deep understanding of various aspects of obesity treatment, metabolic syndrome, and post-procedure management of patients.
“This course should provide students with the knowledge and skills necessary to succeed in the field of regenerative and functional medicine,” said Benito Novas, Managing Director of Global Stem Cells Group and Head of Public Relations for the International Society for Stem Cell Application from the USA. “We are committed to providing students with a comprehensive understanding of the latest advancements in the field and how to effectively care for patients”.
The course covers various key concepts of regenerative and functional medicine for obesity management, and gastric balloon, a safe and effective non-surgical treatment, as one of them. The course will feature in-depth insights into the fundamentals of this procedure and how they can be used to help patients achieve and enjoy healthy weight loss. Additionally, post-procedure management approaches and protocols, will be covered.
Apart from balloon therapy, the course will also explore a wide range of other related topics, such as vitamins, exosomes, trace elements, minerals, hydrolyzed collagen, and more, and their significance in obesity management. These topics should prove useful to practitioners and course other course attendees in understanding metabolic syndrome and the best post-procedure practices for managing patients.
The course will be taught by two highly experienced and well respected professionals in the field of medicine:
Dr. Mario Ojeda, Director and Member of the Chilean Society of Aesthetic Medicine and Surgery (SOCHIMCE). An international reference and renowned expert in various areas, including obesity, intragastric balloons, endoscopic gastroplasty, stem cells, gastroenterology, digestive endoscopy, and colonoscopy, Dr. Mario Ojeda is “pleased to be part of this comprehensive online course and to provide students with the necessary knowledge and skills to advance the field of regenerative and functional medicine.”
Dr. Silvina Pastrana, Head of the ISSCA chapter in Latin America. She is a specialist in general surgery and has extensive experience in aesthetic and anti-aging medicine, orthomolecular medicine and nutrition, cellular therapies, and more. As a trainer in cellular therapies, she is well-equipped to provide students with a comprehensive understanding of the latest advancements in the field.
ISSCA is committed to advancing knowledge in regenerative and functional medicine for better obesity management. This comprehensive online course should provide physicians and specialists with a complete understanding of the latest advancements in the field and how to effectively manage patients, post-procedure.
For more information about the course and how to enroll, please visit the ISSCA visit the ISSCA website, send an email to info@stemcellsgroup.com, or call +1305 560 5337
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advancements in regenerative medicine. It is the educational division of the Global Stem Cells Group focused on promoting excellence and standards in the field of regenerative and functional medicine.
Through training and advancement courses, ISSCA aims to encourage physicians and specialists to practice new and advanced regenerative medicine approaches to benefit patients globally. It also ensures that practitioners learn, meet, and adhere to the necessary regenerative medicine standards and certifications.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in News
Mesenchymal Stem Cells For Cardiovascular Diseases
Despite progress in cardiovascular research, cardiac pathology continues to be one of the most common causes of morbidity and mortality in the world. Stem cell-based therapy has been recognized as an innovative strategy for the repair, regeneration and functional recovery of the myocardium, hence, once the animal research stage has been overcome, most clinical trials aimed at evaluating the safety and effectiveness of regenerative medicine in cardiovascular diseases have focused on angina pectoris, myocardial infarction and chronic cardiomyopathy. Although the current evidence of benefit is not conclusive, the evidence in favor of favorable results is growing.
In some cases, stem cell therapy can provide an effective treatment or alternative for diseases or disorders for which there is no effective treatment. Because these cells are capable of dividing into a wide range of lineages and tissues, they can be used to treat various diseases by repairing, replacing, and regenerating tissues.
It is unclear how umbilical cord mesenchymal stem cells act on the heart, but previous studies have shown that they possess an anti-apoptotic effect. The induced cardiomyocytes can form discs interspersed with myocytes from the host cells, creating a functional syncytium that will help contract the heart. Mesenchymal stem cells can improve cardiac function and reduce damage caused by cardiovascular disease, since they stimulate endogenous repair mechanisms, the regulation of the immune response, tissue perfusion and the proliferation of the resident heart rate, thereby improving cardiac function and reducing damage severity.
Refractory angina
This syndrome, characterized by persistent angina despite standard medical treatment, is often not revascularized due to diffuse coronary lesions or severe comorbidities.
In 2017, a review included 13 clinical studies, with 1061 patients and 12 months of follow-up on average, indicating cell therapy has emerged as a tool for managing these patients. Although the available data are inconclusive, the authors conclude that stem cell-based therapy could be a viable addition to conventional treatment options for refractory angina, given the paucity of therapeutic alternatives.
There was a reduction in mortality at two years after a meta-analysis in 2018, involving 304 patients, showed improved exercise tolerance and reduced angina attack frequency at three, six and 12 months. An additional meta-analysis published in March 2019, involving 526 patients monitored for 14 months, showed that patients treated with stem cells had fewer serious adverse effects, fewer deaths, fewer angina attacks, and fewer antianginal medications than those treated with conventional management.
A third meta-analysis from 2019, with 269 patients and 15 months of follow-up on average, reports the following results: decreased all-cause mortality, decreased frequency of angina and increased exercise time, with no increase in adverse reactions.
Cardiomyopathy (ischemic and non-ischemic)
Despite optimal medical and surgical management, many patients with heart failure undergo long-term myocardial remodeling that does not allow them to restore their ventricular function. This is because current treatment protocols cannot reverse the loss of cardiomyocytes due to cardiomyopathy. Since inflammatory responses continue over time as a central mechanism in the development of heart failure, it was of interest to investigate the anti-inflammatory, antifibrotic, and immunomodulatory properties of stem cells in patients with ischemic and non-ischemic cardiomyopathy.
In a review of five clinical studies published between 2017 and 2018, including 605 patients, the authors conclude that cell therapy is safe, causes immunomodulatory effects, improves functional capacity, and adds clinical benefits to standard therapies. According to them, the results are promising, and further evidence strengthening is recommended.
Based on a meta-analysis published in May 2019, involving 20 investigations and 1418 patients evaluated for an average of 21 months, stem cells improved cardiac function indicators (LVEF and LVESV), walking distance, functional classification of heart failure, quality of life, and mortality as compared to controls. Hospitalizations and serious adverse events were not different from those in the control group.
In a recent review of 9 studies involving 612 patients with heart failure, improvement was found in clinical and paraclinical parameters, evaluated on average for 9 months. According to the authors, stem cells are an effective therapy for the treatment of heart failure, improving patient prognosis and ability to exercise.
Acute myocardial infarction (AMI)
The application of stem cells was associated with a significant increase in left ventricular ejection fraction (LVEF) and other variables indicative of improved ventricular function and modification of remodeling in patients with AMI receiving timely percutaneous coronary intervention (PCI) and conventional medication in different studies. Even coronary artery bypass grafting with stem cells offers greater benefits. A number of studies have also shown that intravenous administration could be a more efficient and effective method of treating the heart or coronary arteries than direct application, with logistic, safety, and cost advantages.
Stem cell therapy is evidenced to be a safe way to treat cardiovascular diseases, as it shows an anti-apoptotic effect, reduction of lesion size, improvement of cardiac function through regulation of the immune response, adequate tissue perfusion and activation of growth factors.
We still need to explore a lot of ground, in terms of these and other conditions. You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us
- Published in Blog
Atherosclerosis obliterans grade IV: Application of Autologous Stem Cells
Atherosclerosis is the most common form of arterial occlusive disease in adults. About 15 percent of adults over 55 years of age suffer from critical ischemia, the most severe form of this disease.
Due to the gradual aging of the population and the growing number of people in their third age group, a number of studies have been conducted in order to improve the prognosis of atherosclerosis obliterans and to find alternatives to the mutilation of the extremities. As a general rule, chronic ischemia of the lower limbs should be treated to alleviate symptoms, particularly pain, prevent disease progression, and reduce the rate of amputations. In most patients with critical ischemia, the main goal is to preserve the affected limb.
The development of regenerative medicine is closely linked to the development of new knowledge about embryonic and adult stem cells, as well as the regenerative and therapeutic potential of stem cell therapy. The use of adult stem cells in the treatment of peripheral artery diseases has been demonstrated as a therapeutic agent for inducing angiogenesis. Recent preclinical studies as well as the pioneering clinical studies indicate that bone marrow-derived mononuclear cells (MBMCs) can enhance tissue vascularization in ischemic limbs, with results similar to those obtained with peripheral blood stem cells supply.
Cuba presented the first studies carried out in 2004 at the Institute of Hematology of the “Enrique Cabrera” hospital in Havana City, which achieved encouraging clinical results and had very few adverse effects in recent years.
A progressive rise in the accumulated experience with stem cells was also observed in Pinar del Rio in 2005, as the first 10 cases were carried out. The rising ease of obtaining this type of cell has made research and applications with these cells advance rapidly with great expectations in terms of clinical application.
A study published by Dia-Diaz, et al. in the Journal of Medical Sciences of Pinar del Rio examined 296 patients with grade IV atherosclerosis obliterans between 2009 and 2019. During the study, autologous stem cells were injected intramuscularly from peripheral blood. Within four weeks, pain relief was observed, as well as an increase in the pain-free claudication distance. Angiography after treatment revealed collateral vessel formation. The limb was saved in 201 patients (68%), while 95 cases (32%) presented amputation criteria. Complications were not reported following the procedure.
The study demonstrated the effectiveness of the implantation of autologous stem cells obtained from peripheral blood, as well as the favorable evolution of patients, clinical improvement of rest pain, walking distance without claudication and ankle-brachial pressure index.
We still need to explore a lot of ground, in terms of these and other conditions. You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us
- Published in Blog
The emerging role of MSC-derived exosomes in Regenerative Medicine
In recent years, MSCs have been introduced as respectable candidates for regenerative medicine due to their pro-angiogenic, anti-apoptotic, and immunomodulatory attributes. A variety of human tissues can be used as a source of mesenchymal stem/stromal cells (MSCs), ranging from bone marrow (BM) to umbilical cord (UC). These cells are typically multipotent and can differentiate into a variety of cell types. MSCs have been studied extensively for potential applications in cardiomyopathy, neurodegenerative disorders, spinal cord injuries (SCI), kidney injuries, liver injuries, lung injuries, and even cancer. According to current research, MSC-derived extracellular vesicles (EVs) contribute to MSC-exerted therapeutic benefits.
As defined by the International Society for Extracellular Vesicles (ISEV), EVs are lipid bilayer particles secreted by cells that do not replicate. EVs can be categorised into three subclasses based on size and biogenesis procedures: surrounding exosomes (50-150 nm), microvesicles (MVs) (100-1000 nm), and apoptotic bodies (ApoBDs) (500-5000 nm). In order for exosomes to be produced, multiple steps must occur; endosomes must be created from the plasma membrane, intraluminal vesicles must be formed within multivesicular bodies by inward budding, the MVB must merge with the plasma membrane, and finally the internal vesicles must be released.
By transmitting their molecules, such as proteins, messenger RNA (mRNA), and microRNAs (miRNAs), MSC exosomes stimulate phenotypic changes and subsequently modify regenerative programs of target organs. A number of mechanisms are involved in phenotypic alterations, including prevention of apoptosis, cell proliferation, immunomodulatory reactions, attenuation of oxidative stress, and improving oxygen supply to recipient cells. By supporting mitochondrial transfer, MSC-exosomes can suppress inflammatory cytokine production and induce phenotype 2 alveolar macrophages (M2), leading to acute lung injury (ALI) rescue. It has been demonstrated that the transmission of miRNAs from MSC-exosomes to recipient cells is responsible for the restoration of damaged kidneys, hearts, livers, and brains
Various cells continuously form and secrete exosomes, including lymphocytes, platelets, mast cells, intestinal epithelium, dendritic cells, neoplastic cell lines, microglia, neurons, and MSCs. Studies have shown that exosomes play an important role in cell-to-cell communication as well as several physiological and pathological processes. Despite their inherent biological activities, exosomes have recently been introduced as encouraging drug carriers because of their small size, high biocompatibility, and ability to hold different therapeutic ingredients, including proteins, nucleic acids, and small molecules. There have been reports showing the usefulness of MSCs-exosomes for treating a variety of ailments, such as lung, kidney, liver, neurodegenerative, cardiac, and musculoskeletal diseases, as well as skin wounds in vivo.
As well as their remarkable therapeutic effects, MSC-EVs derived from diverse sources also possess a variety of physiological functions that may affect their therapeutic application. In a wide range of human disorders, MSC-exosomes are considered an effective alternative to whole-cell therapy because of their low immunogenicity and improved safety profile. Although MSC-exosome applications still face various challenges, their benefits and capabilities are attracting increasing interest.
To learn more about stem cells, exosomes and keep up to date with all the information about regenerative medicine and its advances, sign up for our international certification in regenerative medicine at www.issca.us
- Published in Blog
